Pressmeddelanden, rapporter och bolagsmeddelande för Raisio Oyj Vaihto-osake

Raisio plc will release its Interim Report for January-September 2024 on November 5, 2024, at 8:30 am EET. The report will be available on their website. A Finnish-language webcast for analysts, investors, and media will be held by CEO Pasi Flinkman and CFO Mika Saarinen on the same day at 12:00 EET, with a recording available afterward. An English presentation will be posted on their website. Raisio is conducting a survey to improve financial and investor communications, with a deadline of November 8, 2024. Participants can enter a raffle for a Raisio product prize. Raisio focuses on creating plant-based and heart-healthy foods with brands like Benecol®, Härkis®, and Elovena®, and exports to over 40 markets. Their shares are listed on Nasdaq Helsinki Ltd. In 2023, Raisio's net sales were EUR 219.5 million, with an EBIT of EUR 22.7 million.

Raisio plc announced it will publish its Financial Statements Bulletin for 2024 on 13 February 2025 at 8:30 a.m. Finnish time. Additional financial documents, including the Financial Statement, Board of Directors' Report, Corporate Responsibility information, and Remuneration Report for 2024, will be released in week 11 of 2025. The 2025 financial report release dates are as follows: Interim Report for January−March on 13 May, Half-Year Financial Report for January−June on 12 August, and Interim Report for January−September on 11 November, all at 8:30 a.m. Finnish time. The Annual General Meeting is scheduled for 15 April 2025 in Turku, Finland, with the Board of Directors to summon the meeting later. Shareholders can request agenda items for the meeting by 17 February 2025. Raisio plc focuses on creating plant-based and heart-healthy food products, with brands like Benecol®, Härkis®, and Elovena®. The company operates in seven countries and exports to over 40 markets. In 2023, Raisio's comparable net sales were EUR 219.5 million, and comparable EBIT was EUR 22.7 million. Raisio's shares are listed on Nasdaq Helsinki Ltd.

Raisio plc's Half-Year Financial Report for January-June 2024 highlights a positive trend in their operating environment despite ongoing market challenges. The company reported increased sales volumes and net sales, with a nearly nine percent rise in the second quarter compared to the previous year, reaching EUR 57.3 million. Comparable EBIT grew by almost a third to EUR 7.4 million, or 13.0 percent of net sales. Investments in international growth, marketing, and product development were higher than the comparison period but were offset by higher sales and an improved gross margin. Key drivers of growth included strong performances of their brands, particularly Benecol® and Elovena®, with promising developments in main markets like the UK and Ireland. The company remains optimistic about the long-term potential of the plant protein market despite current challenges. Raisio projects its comparable EBIT for 2024 to be at or slightly above the 2023 level of EUR 22.7 million. The CEO expressed pride in the company's heritage and innovative capabilities. Further details on the financial report will be discussed in a webcast on August 7, 2024.

Raisio plc will release its Half-Year Financial Report for January-June 2024 on Wednesday, 7 August 2024, at approximately 8.30 am EEST. The report will be accessible on their website, www.raisio.com. A webcast for analysts, investors, and media, presented in Finnish by CEO Pasi Flinkman and CFO Mika Saarinen, will take place on the same day at 12.00 EEST. The webcast and its recording can be viewed at https://raisio.videosync.fi/q2-2024. An English presentation slide-deck will be available on their website after the webcast. For further information, contact CFO Mika Saarinen at +358 40 072 6808. Raisio plc focuses on producing plant-based and heart-healthy foods and exports to over 40 markets globally. In 2023, the company's comparable net sales for continuing operations were EUR 219.5 million, with a comparable EBIT of EUR 22.7 million. Raisio's shares are listed on Nasdaq Helsinki Ltd.

Raisio plc announced a manager's transaction involving Pekka Tennilä, a member of the Board. On June 18, 2024, Tennilä received a share-based incentive consisting of 1,654 shares, with a unit price of 0 EUR. Raisio plc, known for its plant-based and heart-healthy products under brands like Benecol®, Härkis®, and Elovena®, operates in over 40 markets worldwide. In 2023, Raisio's net sales for continuing operations were EUR 219.5 million, with a comparable EBIT of EUR 22.7 million. The company's shares are listed on Nasdaq Helsinki Ltd. For further information, contact CFO Mika Saarinen or CLO Sari Koivulehto-Mäkitalo.

Raisio plc announced the conveyance of its own shares as part of the reward for the Chairman and Board members, following a decision made at the Annual General Meeting in April 2024. Approximately 20% of the monthly reward will be paid in shares and 80% in cash, distributed in June and December. On June 18, 2024, Raisio assigned 11,485 shares (RAIVV) valued at EUR 1.922 per share, totaling EUR 22,074.17, to the Chairman and Board members. After this conveyance, Raisio holds 1,190,858 free shares. Raisio plc focuses on producing plant-based and heart-healthy food products, with strong brands like Benecol®, Härkis®, and Elovena®. The company operates in seven countries, exporting to over 40 markets, and is listed on Nasdaq Helsinki Ltd. In 2023, Raisio's net sales were EUR 219.5 million with an EBIT of EUR 22.7 million.